More recently, it is demonstrated in breast cancer and lung cancer that targeting the CD10 + GPR77 + CAFs correlated with chemoresistance and poor survival by using a neutralizing monoclonal antibody against GPR77 could induce tumor formation and improves chemotherapy efficacy in vivo [133]. This evidence concerns the gene C5AR2 and lung carcinoma.